skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Icrucumab (Code C79808)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Icrucumab

Definition: A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1, which may prevent the activation of downstream signaling pathways and so inhibit tumor angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2 signaling.

Display Name: Icrucumab

Label: Icrucumab

NCI Thesaurus Code: C79808 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2703168  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody IMC-18F1
Anti-VEGFR-1 Monoclonal Antibody IMC-18F1

External Source Codes: 
CAS Registry Number 1024603-92-6 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 625428
PDQ Open Trial Search ID 625428 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703168

Other Properties:
     Name Value (qualifiers indented underneath)
code C79808
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-VEGFR-1_Monoclonal_Antibody_IMC-18F1
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom